罕见病创新药维万心®开出华东地区首张处方

2020-12-08 医谷网 医谷网

今日(12月8日),近期在国内获批上市的罕见病创新药物维万心?(氯苯唑酸软胶囊,Vyndamax?,61mg)在上海交通大学医学院附属瑞金医院开出了华东地区首张处方。维万心是全球首个、也是唯一经批准治

今日(12月8日),近期在国内获批上市的罕见病创新药物维万心?(氯苯唑酸软胶囊,Vyndamax?,61mg)在上海交通大学医学院附属瑞金医院开出了华东地区首张处方。维万心是全球首个、也是唯一经批准治疗转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)的口服药物,填补了此前我国ATTR-CM治疗领域无有效药物的空白,为疾病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。

ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在于不稳定甲状腺素蛋白(TTR)的异常解离后的错误折叠,形成淀粉样物质沉积于心肌间质,长期进展会引发限制性心肌病和进行性心力衰竭。

上海瑞金医院心内科金玮教授表示:“ATTR-CM极易与心衰混淆,加之学术界对疾病的认知不足,患者往往因为误诊、漏诊而错过最佳治疗时间,生活质量也因此受到严重影响,临床诊断后平均生存时间仅为2~6年。近年来,我国不同地区已有医院陆续诊断出该疾病,本次创新药物的上市及处方,改变了以往ATTR-CM无药可医的困境,为延长患者生命带来希望。”

瑞金医院积极打造诊疗示范中心(CoE中心),加快实现ATTR-CM早诊早治

由于ATTR-CM是一种累及多系统的疾病,发病症状不典型,往往需要不同科室的专业经验,患者才能确诊,这就更加凸显了提高MDT诊疗能力的重要意义。

目前,ATTR-CM临床诊疗面临众多严峻挑战,国内仅有少数医院具备诊断和治疗能力。作为中国罕见病联盟首批ATTR-CM CoE中心,上海瑞金医院已运用多种诊断方法,并建立起ATTR-CM规范化的诊疗模式。金玮教授表示:“目前,我们已建立了包括心脏内科、核医学科、肾脏内科、神经内科、血液内科、风湿免疫科等学科在内的多学科(MDT)诊疗团队。有能力开展心肌显像、心内膜心肌活检等多种诊断方法,可以大大降低ATTR-CM误诊、漏诊的风险,加快实现早诊早治的目标,本着‘广博慈爱,追求卓越’的精神,我们同时给予罕见病患者深厚的人文关怀,以期未来能够帮助到越来越多的ATTR-CM患者。”

维万心?于2020年9月底获得中国国家药品监督管理局批准,用于治疗成人野生型或遗传型转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM),以减少血管死亡及心血管相关住院。基于该药物的突破创新性,以及对改善人类健康所做出的杰出科学创新,10月30日,维万心?荣获盖伦奖(Prix Galien Awards)最佳生物技术产品奖。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
    2020-12-11 ms4000001839451027

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
    2020-12-10 syscxl
  4. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
    2020-12-10 1de1c5cem92(暂无匿称)

    怎么发现罕见病?

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
    2020-12-10 ms9000001544664399

    病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
    2020-12-09 ms7000002061668254

    可以用了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
    2020-12-09 ms7000002061668254

    挺好

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=906938, encodeId=c94a90693860, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=24e95384371, createdName=ms4000001839451027, createdTime=Fri Dec 11 08:02:05 CST 2020, time=2020-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285958, encodeId=d6271285958f9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467595, encodeId=d81c146e595b4, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Thu Dec 10 14:29:58 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906605, encodeId=9a6d906605c5, content=怎么发现罕见病?, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8c0d1674475, createdName=1de1c5cem92(暂无匿称), createdTime=Thu Dec 10 09:28:21 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906530, encodeId=ef4c906530da, content=病的临床治疗提供了创新性选择,为患者治疗带来了新的希望。 ATTR-CM是一种罕见的、致死性疾病,诊断率不足1%。其发病原理在, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=662a5441223, createdName=ms9000001544664399, createdTime=Thu Dec 10 00:29:48 CST 2020, time=2020-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906228, encodeId=29269062285d, content=可以用了, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:51 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906227, encodeId=fe2090622ec3, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4fd45442729, createdName=ms7000002061668254, createdTime=Wed Dec 09 00:51:20 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906204, encodeId=44eb90620470, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/g?b=oidb&k=GMYXV8iaq7ibgN4T5uIPO9cg&s=100&t=1556427701, createdBy=72ca5247511, createdName=muhu, createdTime=Wed Dec 09 00:08:39 CST 2020, time=2020-12-09, status=1, ipAttribution=)]
    2020-12-09 muhu

    学习

    0

相关资讯

罕见病临床试验网络建设:FDA 加速器计划及反馈意见

过去十年中,在规划和执行罕见病药物开发的临床试验方面取得了一些进展。2018 年,有史以来第一次,美国FDA 批准的大多数新分子实体是用于治疗罕见病的孤儿药。但是在大约 7000 种已知罕见病中,只有

5类罕见病费用每年超百万,“穗岁康”有望部分缓解看病贵问题

国家卫健委罕见病诊疗与保障专家委员会专家,广州市妇女儿童医疗中心遗传与内分泌科主任医师刘丽在接受39健康采访时表示,穗岁康有望部分缓解患者看病贵问题,也望减少部分医患纠纷。

我们为什么要关注罕见病?

罕见病用药困境与抉择。

121种“常见的”罕见病名录,以及我国主要罕见病介绍,请速收藏并转发

中华医学会医学遗传学分会提出的中国罕见病定义,罕见病即患病率低于1/500000或新生儿发病率低于1/10000的疾病。世界上有超过7000种罕见疾病,而且数量在不断增加,每年大约有250种新疾病加入

Bluebird突破性基因疗法Lenti-D申请上市!改善致死罕见病CALD患者长期生存结局

肾上腺脑白质营养不良(adrenoleukodystrophy,ALD)是一种致命性、神经退行性、X连锁隐性遗传病,发病率 0.5/10 万~1/10 万,多见于年轻男孩儿,影响全球大约21000例男